I hesitated while pasting together this Bio-Twitter Year in Review because... Does anyone really want to remember what happened in 2016?
Don't all raise your hands at once; 2016 was a lousy year for biotech investors. It started bad, got worse, perked up, got worse again, rebounded just a little, looked like it was normalizing then tanked -- again.
Still, if we have to look back at the pain, why not have some fun with it? I combed through my Twitter archive to compile a 2016 biotech review in tweets. Month by month, here's how 2016 went -- for you and for me.
You know a bad year is coming when your beloved dog dies right after New Year's Day.
Max died today. We're heartbroken. Lover of tennis balls, water, mud & runs in woods. My best buddy. I miss him. ❤️ pic.twitter.com/o0wRekNdIe— Adam Feuerstein (@adamfeuerstein) January 4, 2016
MannKind (MNKD) kaboom!
Another bad omen for 2016: A news-free start to the J.P. Morgan Healthcare conference.
This! (Followed fast by the FDA's decision to postpone the Sarepta (SRPT) advisory panel.)
$SRPT — eteplirsen dystrophin production better than drisapersen but not saying much. 0.9% of normal. Yikes.— Adam Feuerstein (@adamfeuerstein) January 15, 2016
Biotech stocks cratered...
By the end of January, there was nowhere for investors to hide...
No, dumbass, four more years of Trump!
Can someone please remind me. If Punxsutawney Phil sees his shadow tomorrow, does that mean six more weeks of Trump?— Adam Feuerstein (@adamfeuerstein) February 1, 2016
And surely someone shouted, "Buy the Gilead (GILD) dip!"
$GILD 2016 net product sales guidance $30-31B versus actual 2015 net product sales $32.2B— Adam Feuerstein (@adamfeuerstein) February 2, 2016
The only good news I had in 2016.
When your daughter receives a letter saying she was accepted to college. pic.twitter.com/uXKeOG6ViK— Adam Feuerstein (@adamfeuerstein) February 18, 2016
Dr. Robert Califf, the new FDA commissioner.— Adam Feuerstein (@adamfeuerstein) February 24, 2016
We were so hopeful, but we're still waiting...
Taking out the trash.
This list... UpdatedFebruary 25, 2016
Al Mann, 90, is dead. $MNKD was an anomaly in a hugely successful career as businessman, generous philanthropist. Peace to his family.— Adam Feuerstein (@adamfeuerstein) February 26, 2016
My new best friend.
Big news! Meet new member of my family. Just adopted. We'll be picking up this cutie this wknd or next. Dog ❤️!! pic.twitter.com/2FRwUSh2wP— Adam Feuerstein (@adamfeuerstein) February 29, 2016
Celldex (CLDX) blew up, one of many this year.
$CLDX Rintega "ACT IV" ph3 brain tumor study stopped for futility at interim analysis. I had hope for this one, but not to be. Fail.— Adam Feuerstein (@adamfeuerstein) March 7, 2016
Valeant (VRX) was a dumpster fire.
pearson out $VRX— zach (@zbiotech) March 21, 2016
Yes, Q1 was bad.
It's over! "It" is the 4th-worst quarter for biotech stocks ever. Moving on... https://t.co/Vc9Wv67qxW— Adam Feuerstein (@adamfeuerstein) April 1, 2016
THE FDA adcomm of 2016.
The outcome looked bleak, but...
$SRPT — I know we focus mostly on stocks here but there should be no joy or gloating over the negative panel vote. This was really tough.— Adam Feuerstein (@adamfeuerstein) April 25, 2016
There was this....
M&A in May! (Just not enough of it.)
The wait continued.
$SRPT Announces FDA Will Not Complete The Review Of The Eteplirsen NDA By The PDUFA Date— Bio Stocks™ (@BioStocks) May 25, 2016
Anyone want to take back their choice?
The biotech circle of life.
And on and on it goes. Biotech Summer 2016.— Adam Feuerstein (@adamfeuerstein) June 20, 2016
The year started bad, and never really stopped being bad.
Been thinking about the mid-way point of the year in biotech stocks and life science. This just about sums it up. pic.twitter.com/ehRZsL8brX— Adam Feuerstein (@adamfeuerstein) June 30, 2016
$JUNO clinical hold JACAR015— Brad Loncar (@bradloncar) July 7, 2016
$MNKD, at investor conference earlier this week, excited Afrezza NRx are "stabilizing."
Squint, you might see it. pic.twitter.com/nHsPTEEK7d— Adam Feuerstein (@adamfeuerstein) July 15, 2016
Drug pricing was the issue that never went away in 2016.
$ARIA has taken another +9% price increase on Iclusig in July after +8% in April and +9% in Jan.
Price hike now once per quarter...— Andy Biotech (@AndyBiotech) July 29, 2016
Bristol-Myers Squibb (BMY) committed one of the biggest "oops!" of 2016.
And there were gifs...
It was a great ride.
We were still waiting...
Medivation (MDVN) delivered.
She's settled in her dorm. The goodbye was hard. You raise her, watch over her, love her with all your being and then you let her fly. ❤️❤️— Adam Feuerstein (@adamfeuerstein) September 3, 2016
POLL: $SRPT -- Will FDA approve eteplirsen in this review cycle i.e. No more data needed?— Adam Feuerstein (@adamfeuerstein) September 9, 2016
Finally! But the arguments and doubts followed fast.
And there it is…. $SRPT eteplirsen approved.
FDA letter —> https://t.co/KoxupYjLIb— Adam Feuerstein (@adamfeuerstein) September 19, 2016
We made fun of sell-side analysts a lot in 2016. Mostly, they deserved it.
CTI Biopharma (CTIC) CEO Jim Bianco resigns: W.O.A.T.
Dear Jim Bianco: pic.twitter.com/uIbMCWwaDy— Adam Feuerstein (@adamfeuerstein) October 3, 2016
Ariad Pharma (ARIA) does it wrong.
Alnylam (ALNY) -- yet another biotech blowup in 2016.
Alnylam Pharmaceuticals Discontinues Revusiran Development $ALNY— zach (@zbiotech) October 5, 2016
POLL! Please vote. Describe your healthcare investing mood right now, as Q3 earnings draw to close.— Adam Feuerstein (@adamfeuerstein) November 1, 2016
We can praise the sell-side, too.
Little did we know at that time, Alexion (ALXN)
$ALXN 10-Q, where art thou?— Adam Feuerstein (@adamfeuerstein) November 9, 2016
The brief Trump Bump.
And on the same day!
But the beta-amyloid hypothesis lives on...
I just came out of seeing "Manchester by the Sea" (good movie) and see the BETA AMYLOID HYPOTHESIS LIVES ON. pic.twitter.com/nv39HutrBX— Adam Feuerstein (@adamfeuerstein) December 9, 2016
Let's hope 2017 is better than 2016. It could hardly be worse.